Source: Eur Respir J 2002; 20: 975-981
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Meert A-P., Martin B., Delmotte P., Berghmans T., Lafitte J-J., Mascaux C., Paesmans M., Steels E., Verdebout J-M., Sculier J-P.. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002; 20: 975-981

Member's Comments

No comment yet.

Related content which might interest you: The role of EGFR expression in the survival of patients with lung cancer: a systematic review of the literature with meta-analysis Source: Eur Respir J 2001; 18: Suppl. 33, 478s Year: 2001 Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis Source: Eur Respir J 2001; 18: 705-719 Year: 2001 Role of ras protoncogene in survival of patients with lung cancer: a systematic literature review and meta-analysis Source: Eur Respir J 2004; 24: Suppl. 48, 478s Year: 2004 The role of angiogenesis, assessed by microvessel count (MVC), on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis Source: Eur Respir J 2002; 20: Suppl. 38, 3s Year: 2002 COX-2 as prognostic factor in lung cancer: systematic review of the literature with meta-analysis Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up Source: Eur Respir J 2009; 33: 436-440 Year: 2009 A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations Source: Annual Congress 2006 - Lung cancer treatment Year: 2006 Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer Source: Eur Respir J 2011; 37: 183-193 Year: 2011 Nationwide real-world cohort study of first line TKI treatment in epidermal growth factor receptor mutated non-small cell lung cancer. Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Epidermal growth factor receptor mutation status in advanced non-small cell lung cancer: A single institution experience Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis Source: ERJ Open Res, 5 (4) 00179-2019; 10.1183/23120541.00179-2019 Year: 2019 The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004 A blood-based test for epidermal growth factor receptor mutations in patients with non-small cell lung cancer Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008 Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung cancer and its correlation with survival Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009 Epithelial growth factor receptor (EGFR) mutation status and the treatment of non-small cell lung cancer (NSCLC): A population based quality assurance analysis Source: International Congress 2015 – Quality management in lung cancer Year: 2015 Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 366-372 Year: 2012 Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer Source: Eur Respir J 2005; 25: 329-335 Year: 2005 Detection of epidermal growth factor receptor mutation in plasma as predictor of gefitinib response in non small cell lung cancer Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008